临床实践指南:突发性听力损失(更新版)
该指南更新由美国耳鼻咽喉头颈外科学会基金会制定,聚焦18岁及以上成人突发性听力损失,尤其是特发性突发感音神经性听力损失。指南强调初诊时区分感音神经性与传导性听力损失,症状出现14天内尽快行听力检查确诊,并通过MRI或听性脑干反应评估蜗后病变。指南强烈推荐不常规行头颅CT、不常规行实验室检查、不常规处方抗病毒药、溶栓药、血管扩张药或血管活性物质;可考虑发病2周内初始糖皮质激素治疗,以及发病2周内或1个月内挽救性高压氧联合类固醇治疗。
要点
- 初诊突发性听力损失时,临床医生应区分感音神经性与传导性听力损失(强推荐)。
- 疑似突发感音神经性听力损失应通过病史和体格检查评估双侧突发、复发性发作和/或局灶性神经体征(推荐)。
- 突发性听力损失应在症状出现14天内尽快完成或转诊完成听力检查以确诊(推荐)。
- 不常规处方抗病毒药、溶栓药、血管扩张药或血管活性物质(强推荐反对)。
- 发病2周内可考虑初始糖皮质激素治疗;发病2~6周不完全恢复者可提供鼓室内类固醇治疗(推荐)。
适用人群与场景
- 成人(年龄≥18岁)突发性听力损失患者,主要针对特发性突发感音神经性听力损失。
- 适用于所有诊断或管理成人突发性听力损失的临床医生。
诊断标准与关键阈值
- 初诊突发性听力损失时需区分感音神经性听力损失与传导性听力损失。
- 疑似突发感音神经性听力损失需通过病史和体格检查评估双侧突发听力损失、复发性突发听力损失发作和/或局灶性神经体征。
- 通过听力检查确诊突发感音神经性听力损失,应尽可能早、在症状出现14天内完成。
处置流程与药物剂量
- 突发性听力损失初诊时区分感音神经性与传导性听力损失(强推荐)。
- 疑似突发感音神经性听力损失通过病史和体格检查评估双侧突发、复发性发作和/或局灶性神经体征(推荐)。
- 突发性听力损失应尽快(症状出现14天内)获取或转诊获取听力检查以确诊(推荐)。
- 突发感音神经性听力损失通过MRI或听性脑干反应评估蜗后病变(推荐)。
- 发病2周内可考虑初始糖皮质激素治疗(选项)。
- 发病2周内可考虑高压氧联合类固醇治疗(选项)。
- 发病1个月内可考虑高压氧联合类固醇作为挽救治疗(选项)。
- 发病2~6周不完全恢复者可提供或转诊提供鼓室内类固醇治疗(推荐)。
红旗征与不能漏的情况
- 双侧突发性听力损失、复发性突发性听力损失发作和/或局灶性神经体征需通过病史和体格检查评估。
- 需识别罕见的非特发性突发感音神经性听力损失,以区别于特发性突发感音神经性听力损失。
研究设计与关键结果
- 指南更新组纳入10部临床实践指南、29篇新系统评价和36项新随机对照试验。
- 强推荐:初诊突发性听力损失时区分感音神经性与传导性听力损失(KAS 1)。
- 强推荐:向突发感音神经性听力损失患者宣教疾病自然史、医疗干预的获益与风险及现有疗效证据的局限性(KAS 7)。
- 强推荐:向有残余听力损失和/或耳鸣的突发感音神经性听力损失患者宣教听力康复和其他支持措施的可能获益(KAS 13)。
- 强推荐反对:初诊疑似突发感音神经性听力损失不常规行头颅CT(KAS 3)。
- 强推荐反对:突发感音神经性听力损失不常规行实验室检查(KAS 5)。
- 强推荐反对:不常规处方抗病毒药、溶栓药、血管扩张药或血管活性物质(KAS 11)。
- 推荐:突发感音神经性听力损失治疗结束时及治疗完成后6个月内行随访听力检查(KAS 12)。
证据类型、等级与局限
- 证据类型:临床实践指南(更新版),基于系统文献综述。
- 方法:遵循美国耳鼻咽喉头颈外科学会基金会《临床实践指南制定手册(第3版)》。
- 关键行动声明附有证据概况、证据信心和意见差异。
- 局限:原文未报告局限性
对床旁实践的改变
- 急诊/ICU接诊成人突发性听力损失时,应先区分感音神经性与传导性听力损失,而不是直接按突发性聋处理。
- 不常规开具头颅CT、不常规行实验室检查,避免非靶向检查;靶向颞骨CT等不在此反对范围。
- 不常规使用抗病毒药、溶栓药、血管扩张药或血管活性物质。
- 症状出现14天内尽快完成听力检查确诊,确诊后通过MRI或听性脑干反应评估蜗后病变。
- 发病2周内可考虑初始糖皮质激素;发病2~6周不完全恢复者可提供鼓室内类固醇;发病2周内或1个月内可考虑高压氧联合类固醇。
- 治疗结束时及完成后6个月内随访听力检查。
指南或共识出处
- Clinical Practice Guideline: Sudden Hearing Loss (Update), American Academy of Otolaryngology-Head and Neck Surgery Foundation, Otolaryngol Head Neck Surg.
提炼说明
- 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: Sudden hearing loss is a frightening symptom that often prompts an urgent or emergent visit to a health care provider. It is frequently but not universally accompanied by tinnitus and/or vertigo. Sudden sensorineural hearing loss affects 5 to 27 per 100,000 people annually, with about 66,000 new cases per year in the United States. This guideline update provides evidence-based recommendations for the diagnosis, management, and follow-up of patients who present with sudden hearing loss. It focuses on sudden sensorineural hearing loss in adult patients aged ≥18 years and primarily on those with idiopathic sudden sensorineural hearing loss. Prompt recognition and management of sudden sensorineural hearing loss may improve hearing recovery and patient quality of life. The guideline update is intended for all clinicians who diagnose or manage adult patients who present with sudden hearing loss.
PURPOSE: The purpose of this guideline update is to provide clinicians with evidence-based recommendations in evaluating patients with sudden hearing loss and sudden sensorineural hearing loss, with particular emphasis on managing idiopathic sudden sensorineural hearing loss. The guideline update group recognized that patients enter the health care system with sudden hearing loss as a nonspecific primary complaint. Therefore, the initial recommendations of this guideline update address distinguishing sensorineural hearing loss from conductive hearing loss at the time of presentation with hearing loss. They also clarify the need to identify rare, nonidiopathic sudden sensorineural hearing loss to help separate those patients from those with idiopathic sudden sensorineural hearing loss, who are the target population for the therapeutic interventions that make up the bulk of the guideline update. By focusing on opportunities for quality improvement, this guideline should improve diagnostic accuracy, facilitate prompt intervention, decrease variations in management, reduce unnecessary tests and imaging procedures, and improve hearing and rehabilitative outcomes for affected patients.
METHODS: Consistent with the American Academy of Otolaryngology-Head and Neck Surgery Foundation's "Clinical Practice Guideline Development Manual, Third Edition" (Rosenfeld et al. Otolaryngol Head Neck Surg. 2013;148[1]:S1-S55), the guideline update group was convened with representation from the disciplines of otolaryngology-head and neck surgery, otology, neurotology, family medicine, audiology, emergency medicine, neurology, radiology, advanced practice nursing, and consumer advocacy. A systematic review of the literature was performed, and the prior clinical practice guideline on sudden hearing loss was reviewed in detail. Key Action Statements (KASs) were updated with new literature, and evidence profiles were brought up to the current standard. Research needs identified in the original clinical practice guideline and data addressing them were reviewed. Current research needs were identified and delineated.
RESULTS: The guideline update group made strong recommendations for the following: (KAS 1) Clinicians should distinguish sensorineural hearing loss from conductive hearing loss when a patient first presents with sudden hearing loss. (KAS 7) Clinicians should educate patients with sudden sensorineural hearing loss about the natural history of the condition, the benefits and risks of medical interventions, and the limitations of existing evidence regarding efficacy. (KAS 13) Clinicians should counsel patients with sudden sensorineural hearing loss who have residual hearing loss and/or tinnitus about the possible benefits of audiologic rehabilitation and other supportive measures. These strong recommendations were modified from the initial clinical practice guideline for clarity and timing of intervention. The guideline update group made strong recommendations against the following: (KAS 3) Clinicians should not order routine computed tomography of the head in the initial evaluation of a patient with presumptive sudden sensorineural hearing loss. (KAS 5) Clinicians should not obtain routine laboratory tests in patients with sudden sensorineural hearing loss. (KAS 11) Clinicians should not routinely prescribe antivirals, thrombolytics, vasodilators, or vasoactive substances to patients with sudden sensorineural hearing loss. The guideline update group made recommendations for the following: (KAS 2) Clinicians should assess patients with presumptive sudden sensorineural hearing loss through history and physical examination for bilateral sudden hearing loss, recurrent episodes of sudden hearing loss, and/or focal neurologic findings. (KAS 4) In patients with sudden hearing loss, clinicians should obtain, or refer to a clinician who can obtain, audiometry as soon as possible (within 14 days of symptom onset) to confirm the diagnosis of sudden sensorineural hearing loss. (KAS 6) Clinicians should evaluate patients with sudden sensorineural hearing loss for retrocochlear pathology by obtaining magnetic resonance imaging or auditory brainstem response. (KAS 10) Clinicians should offer, or refer to a clinician who can offer, intratympanic steroid therapy when patients have incomplete recovery from sudden sensorineural hearing loss 2 to 6 weeks after onset of symptoms. (KAS 12) Clinicians should obtain follow-up audiometric evaluation for patients with sudden sensorineural hearing loss at the conclusion of treatment and within 6 months of completion of treatment. These recommendations were clarified in terms of timing of intervention and audiometry and method of retrocochlear workup. The guideline update group offered the following KASs as options: (KAS 8) Clinicians may offer corticosteroids as initial therapy to patients with sudden sensorineural hearing loss within 2 weeks of symptom onset. (KAS 9a) Clinicians may offer, or refer to a clinician who can offer, hyperbaric oxygen therapy combined with steroid therapy within 2 weeks of onset of sudden sensorineural hearing loss. (KAS 9b) Clinicians may offer, or refer to a clinician who can offer, hyperbaric oxygen therapy combined with steroid therapy as salvage therapy within 1 month of onset of sudden sensorineural hearing loss.
DIFFERENCES FROM PRIOR GUIDELINE: Incorporation of new evidence profiles to include quality improvement opportunities, confidence in the evidence, and differences of opinion Included 10 clinical practice guidelines, 29 new systematic reviews, and 36 new randomized controlled trials Highlights the urgency of evaluation and initiation of treatment, if treatment is offered, by emphasizing the time from symptom occurrence Clarification of terminology by changing potentially unclear statements; use of the term sudden sensorineural hearing loss to mean idiopathic sudden sensorineural hearing loss to emphasize that >90% of sudden sensorineural hearing loss is idiopathic sudden sensorineural hearing loss and to avoid confusion in nomenclature for the reader Changes to the KASs from the original guideline: KAS 1-When a patient first presents with sudden hearing loss, conductive hearing loss should be distinguished from sensorineural. KAS 2-The utility of history and physical examination when assessing for modifying factors is emphasized. KAS 3-The word "routine" is added to clarify that this statement addresses nontargeted head computerized tomography scan that is often ordered in the emergency room setting for patients presenting with sudden hearing loss. It does not refer to targeted scans, such as temporal bone computerized tomography scan, to assess for temporal bone pathology. KAS 4-The importance of audiometric confirmation of hearing status as soon as possible and within 14 days of symptom onset is emphasized. KAS 5-New studies were added to confirm the lack of benefit of nontargeted laboratory testing in sudden sensorineural hearing loss. KAS 6-Audiometric follow-up is excluded as a reasonable workup for retrocochlear pathology. Magnetic resonance imaging, computerized tomography scan if magnetic resonance imaging cannot be done, and, secondarily, auditory brainstem response evaluation are the modalities recommended. A time frame for such testing is not specified, nor is it specified which clinician should be ordering this workup; however, it is implied that it would be the general or subspecialty otolaryngologist. KAS 7-The importance of shared decision making is highlighted, and salient points are emphasized. KAS 8-The option for corticosteroid intervention within 2 weeks of symptom onset is emphasized. KAS 9-Changed to KAS 9A and 9B. Hyperbaric oxygen therapy remains an option but only when combined with steroid therapy for either initial treatment (9A) or salvage therapy (9B). The timing of initial therapy is within 2 weeks of onset, and that of salvage therapy is within 1 month of onset of sudden sensorineural hearing loss. KAS 10-Intratympanic steroid therapy for salvage is recommended within 2 to 6 weeks following onset of sudden sensorineural hearing loss. The time to treatment is defined and emphasized. KAS 11-Antioxidants were removed from the list of interventions that the clinical practice guideline recommends against using. KAS 12-Follow-up audiometry at conclusion of treatment and also within 6 months posttreatment is added. KAS 13-This statement on audiologic rehabilitation includes patients who have residual hearing loss and/or tinnitus who may benefit from treatment. Addition of an algorithm outlining KASs Enhanced emphasis on patient education and shared decision making with tools provided to assist in same.
参考来源
- Chandrasekhar SS, Tsai Do BS, Schwartz SR, et al. Clinical Practice Guideline: Sudden Hearing Loss (Update). Otolaryngol Head Neck Surg. 2019. PMID: 31369359. doi:10.1177/0194599819859885
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。